HAIRY CELL LEUKEMIA
Clinical trials for HAIRY CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new HAIRY CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for HAIRY CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare leukemia: drug targets MEK gene in BRAF-Negative patients
Disease control Recruiting nowThis study tests a drug called binimetinib for people with hairy cell leukemia that does not have the common BRAF gene mutation. The drug targets a different gene, MEK, which is often altered in these patients. The goal is to see if it can shrink or control the cancer in 40 adult…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising combo targets rare leukemia
Disease control Recruiting nowThis study tests a two-step treatment for hairy cell leukemia, a rare blood cancer. First, patients receive chemotherapy (cladribine) to kill cancer cells, then an immunotherapy drug (rituximab) to help the immune system attack any remaining cells. The goal is to see if adding ri…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo aims to tackle hairy cell leukemia
Disease control Recruiting nowThis study tests a combination of two drugs, tovorafenib and rituximab, in people with hairy cell leukemia that has returned or not responded to treatment, and also compares it to standard therapy for newly diagnosed patients. Tovorafenib blocks a protein that helps cancer grow, …
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for hairy cell leukemia: Chemo-Free combo tested
Disease control Recruiting nowThis study tests whether a combination of two non-chemotherapy drugs (vemurafenib and obinutuzumab) causes fewer side effects than the standard chemotherapy-based treatment (cladribine and rituximab) in people with untreated hairy cell leukemia. About 86 adults with a specific ge…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take on rare leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment for hairy cell leukemia (HCL) that has come back or not responded to standard care. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. Up to 27 adults will receive chemo…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill takes on tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental oral drug called LP-168 in about 60 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and to see how the drug behaves in the body…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New mRNA CAR-T therapy aims to tackle tough blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that uses mRNA to target two proteins (CD19 and CD20) on cancer cells. It is for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The goal is to see if it is safe and effective, with up to …
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC